{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:47:43Z","timestamp":1777420063588,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T00:00:00Z","timestamp":1366675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>An extended-release niacin product (Niaspan, Abbott Laboratories) was identified as a product with a less costly therapeutic alternative; a therapeutic product interchange was implemented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of a product therapeutic interchange from Niaspan to a controlled-release niacin product (Slo-Niacin, Upsher-Smith Laboratories) among patients at a large US Department of Veterans Affairs health care facility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Patients with active prescriptions for Niaspan underwent a therapeutic product interchange to Slo-Niacin; following conversion of the product, the medical record for each patient was reviewed and pre- and postconversion clinical information and conversion details were transcribed into a database for subsequent analysis and study. The primary efficacy end point was pre- and postconversion level of low-density lipoprotein cholesterol; secondary efficacy end points were levels of serum total cholesterol, high-density lipoprotein cholesterol, and triglycerides. Abnormal serum liver enzyme levels greater than 3 times the upper limits of normal was the primary safety end point; blood hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      was assessed as a secondary safety end point.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 5321 patients' medical records were reviewed; for the efficacy evaluation, 539 patients were maintained on a daily dose of Slo-Niacin that was the same as the previous Niaspan dose. The dosage of any other concurrently prescribed dyslipidemia medication was unchanged. Analysis of these cases indicated that the conversion of Niaspan to Slo-Niacin was not associated with a difference in serum lipids over a mean (SD) of 503.9 (98.0) postconversion observation days with the exception of a decrease in mean serum triglyceride concentration of 19.8 mg\/dL (p = 0.0003). Evaluation of all 5321 patients given Slo-Niacin for up to 724 days did not detect any safety differences between Slo-Niacin and Niaspan. Local facility cost avoidance exceeded $800,000 in the first postconversion year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Data from a medication use evaluation of modified-release niacin products therapeutic interchange in a large US Department of Veterans Affairs health care facility show that the switch from Niaspan to Slo-Niacin had no negative effects on lipid-altering efficacy or safety but generated significant cost avoidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r736","type":"journal-article","created":{"date-parts":[[2013,4,24]],"date-time":"2013-04-24T00:09:20Z","timestamp":1366762160000},"page":"657-664","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety Evaluation of a Large Niacin Therapeutic Interchange Program"],"prefix":"10.1177","volume":"47","author":[{"given":"Michael O","family":"Chaffman","sequence":"first","affiliation":[{"name":"Michael O Chaffman PharmD BCPS, at time of writing, Clinical Pharmacy Coordinator, Veterans Affairs Bay Pines Healthcare System, Bay Pines, FL; now, Associate Chief, Pharmacy Service, Orlando Veterans Affairs Medical Center, Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B","family":"Webster","sequence":"additional","affiliation":[{"name":"William B Webster PharmD FCCP BCPS, Clinical Pharmacist\/Consultant, Veterans Affairs Bay Pines Healthcare System"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T","family":"Winiecki","sequence":"additional","affiliation":[{"name":"John T Winiecki PharmD, Clinical Pharmacy Specialist in Informatics, Bay Pines Healthcare System"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,4,23]]},"reference":[{"key":"bibr1-aph.1R736","unstructured":"1. World Health Organization. Cardiovascular disease (Fact Sheet No 317), January 2011. www.who.int\/mediacentre\/factsheets\/fs317\/en\/index.html (accessed 2012, Jun 1)."},{"key":"bibr2-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192667"},{"key":"bibr3-aph.1R736","unstructured":"3. National Heart, Lung, and Blood Institute. NHLBI factbook: 2010. www.nhlbi.nih.gov\/about\/factbook\/chapter4.htm (accessed 2011 Jul 4)."},{"key":"bibr4-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.7.697"},{"key":"bibr5-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1177\/1074248410361337"},{"key":"bibr6-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"bibr7-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1112346"},{"key":"bibr8-aph.1R736","unstructured":"8. O'Riordan M. HPS-2 THRIVE misses primary end point: no benefit of niacin\/Laropiprant. www.theheart.org\/article\/1490635.do (accessed 2012 Dec 28)."},{"key":"bibr9-aph.1R736","unstructured":"9. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2012. http:\/\/content.onlinejacc.org (accessed 2012 Dec 28)."},{"key":"bibr10-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/60.suppl_2.S9"},{"key":"bibr11-aph.1R736","volume-title":"Package insert. Niaspan (niacin extended-release)","year":"2010"},{"key":"bibr12-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.018"},{"key":"bibr13-aph.1R736","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100696"},{"key":"bibr14-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11.1666"},{"key":"bibr15-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"bibr16-aph.1R736","unstructured":"16. Drugs.com. Pharmaceutical sales 2010: top 200 drugs for 2010 by sales. www.drugs.com\/top200.html (accessed 2012 Jun 1)."},{"key":"bibr17-aph.1R736","unstructured":"17. US patent 7011848. Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefore. www.patentstorm.us\/patents\/7011848\/description.html (accessed 2012 Jun 1)."},{"key":"bibr18-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01471-5"},{"key":"bibr19-aph.1R736","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0535"},{"key":"bibr20-aph.1R736","unstructured":"20. Product information. Slo-Niacin (polygel controlled-release niacin) Maple Grove, MN: Upsher-Smith Laboratories, Inc., February 2011. www.slo-niacin.com\/wp-content\/uploads\/2010\/03\/sloniacin-product-info.pdf (accessed 2012 Nov 11)."},{"key":"bibr21-aph.1R736","unstructured":"21. Upsher-Smith Laboratories, Inc. Sales support playbook. Maple Grove, MN, 2010. http:\/\/s3images.coroflot.com\/user_files\/individual_files\/original_466990_49PWkFsE3M8krgKkEe2PR6fHu.pdf (accessed 2012 Nov 11)."},{"key":"bibr22-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2009.04.052"},{"key":"bibr23-aph.1R736","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060089"},{"key":"bibr24-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(92)90170-F"},{"key":"bibr25-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.04.003"},{"key":"bibr26-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90868-Y"},{"key":"bibr27-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60824-6"},{"key":"bibr28-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00303-2"},{"key":"bibr29-aph.1R736","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-4-199408150-00003"},{"key":"bibr30-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011090"},{"key":"bibr31-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22442"},{"key":"bibr32-aph.1R736","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2008.00566.x"},{"key":"bibr33-aph.1R736","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090641"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R736","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:51Z","timestamp":1777374771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,23]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1345\/aph.1R736"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r736","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,23]]}}}